Lifecore Biomedical, Inc. De (LFCR) EBIT Margin (2010 - 2025)

Lifecore Biomedical's EBIT Margin history runs 16 years deep, the most recent figure standing at 14.62% for Q2 2025.

• In Q2 2025, EBIT Margin rose 894.0% year-over-year to 14.62%; the TTM figure through May 2025 stood at 13.38% (down 649.0% YoY), while the FY2025 annual figure was 13.38%, down 649.0% from the prior year.
• EBIT Margin was 14.62% for Q2 2025 at Lifecore Biomedical, up from 25.68% in the prior quarter.
• In the past five years, EBIT Margin ranged from a high of 14.62% in Q2 2025 to a low of 46.89% in Q3 2024.
• Historically, EBIT Margin has averaged 13.35% across 5 years, with a median of 14.28% in 2021.
• The sharpest annual moves came in 2021 and 2022: EBIT Margin surged 2784 bps in 2021, then slumped 3889 bps in 2022.
• A 5-year view of EBIT Margin shows it stood at 14.41% in 2021, then tumbled by 270 bps to 24.48% in 2022, then jumped by 80 bps to 4.92% in 2023, then declined by 22 bps to 6.02% in 2024, then surged by 343 bps to 14.62% in 2025.
• The last three EBIT Margin figures came in at 14.62% (Q2 2025), 25.68% (Q1 2025), and 6.02% (Q4 2024), per Business Quant data.